n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with mrs 1523 in 6 studies
| Studies (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Trials (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Recent Studies (post-2010) (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Studies (mrs 1523) | Trials (mrs 1523) | Recent Studies (post-2010) (mrs 1523) |
|---|---|---|---|---|---|
| 214 | 5 | 58 | 42 | 0 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobson, KA; Ji, XD; Li, AH; Melman, N; Moro, S | 1 |
| Barak, D; Biadatti, T; Chen, W; Gao, ZG; Jacobson, KA; Johnson, CR; Kim, SG; Kim, SK; Lee, K | 1 |
| Donegan, RK; Lieberman, RL | 1 |
| Campbell, RG; Chen, E; Gao, ZG; Jacobson, KA; Liston, TE; Poe, RB; Salmaso, V; Suresh, RR | 1 |
| Bar-Yehuda, S; Barer, F; Erlanger, A; Fishman, P; Madi, L; Ochaion, A; Ohana, G | 1 |
| Castonguay, A; Chen, Z; Cottet, M; De Koninck, Y; Doyle, T; Egan, TM; Ford, A; Jacobson, KA; Little, JW; Salvemini, D; Symons-Liguori, AM; Tosh, DK; Vanderah, TW | 1 |
1 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and mrs 1523
| Article | Year |
|---|---|
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; Glaucoma; Humans; Ligands; Protein Kinase Inhibitors; rho-Associated Kinases; Sympathomimetics | 2016 |
5 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and mrs 1523
| Article | Year |
|---|---|
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
Topics: Adenosine; Animals; Binding, Competitive; Brain; Dihydropyridines; Drug Design; Humans; Iodine Radioisotopes; Kinetics; Models, Molecular; Molecular Conformation; Molecular Structure; Purinergic P1 Receptor Antagonists; Pyridines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A3; Recombinant Proteins; Structure-Activity Relationship | 1998 |
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
Topics: Adenosine; Animals; Binding, Competitive; CHO Cells; Cricetinae; Epoxy Compounds; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Models, Molecular; Mutation; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Radioligand Assay; Rats; Receptor, Adenosine A3; Receptors, Purinergic P1; Ribose; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship | 2002 |
Selective A
Topics: | 2022 |
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
Topics: Adenosine; Animals; beta Catenin; Carcinoma; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Cytoskeletal Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Humans; Indoles; Lithium; Maleimides; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins c-myc; Purinergic P1 Receptor Agonists; Pyridines; Trans-Activators | 2004 |
Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Hyperalgesia; K Cl- Cotransporters; Male; Mice; Pain Threshold; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Sciatica; Signal Transduction; Spinal Nerve Roots; Symporters; Thiazoles; Thioglycolates | 2015 |